Springworks Therapeutics, Inc., A Healthcare Company Of Merck Kgaa, Darmstadt, Germany
Clinical trials sponsored by Springworks Therapeutics, Inc., A Healthcare Company Of Merck Kgaa, Darmstadt, Germany, explained in plain language.
-
Last-Resort drug access opens for rare tumor patients
Disease control AVAILABLEThis program provides mirdametinib to individual patients with severe, life-threatening neurofibromatosis type 1 (NF1) or other MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. The goal is to control the disease when standard therapies …
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New drug trial aims to protect fertility in women with rare tumors
Disease control Recruiting nowThis study tests a drug called nirogacestat in 50 premenopausal women with desmoid tumors (a type of non-cancerous growth). The main goal is to see how the drug affects ovarian function, such as menstrual periods and hormone levels. Participants will take the drug and be monitore…
Phase: PHASE4 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Last-Resort drug access for rare tumor patients
Disease control AVAILABLEThis program provides nirogacestat to individual patients with serious desmoid tumors or NOTCH gene mutation positive tumors who have no other treatment options and cannot join a clinical trial. The goal is to control the disease when standard therapies have failed. Approval is n…
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 18, 2026 12:13 UTC